| HOME >> MEDICINE >> TECHNOLOGY |
NUTLEY, N.J., Oct. 17 /PRNewswire/ -- Ten abstracts providing new analyses of data from six major Phase III renal anemia studies for MIRCERA(R) will be presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on November 2 - 5, 2007.
Among the highlights will be new analyses from maintenance studies, including MAXIMA, PROTOS, STRIATA and RUBRA, and correction studies, including ARCTOS and AMICUS.
Please note all information presented at the ASN annual meeting is embargoed for media release until one hour after the time of presentation.
Abstracts accepted for the ASN annual meeting include:
-- Once-monthly intravenous (IV) C.E.R.A. maintains stable hemoglobin (Hb)
in dialysis patients (pts), irrespective of age or gender. S. Fishbane
et al. (SU-PO779. November 4: 10:00 a.m. - 12:00 p.m. PST. Exhibit
Hall, Moscone Center)
-- Stable hemoglobin (Hb) levels are maintained with once-monthly C.E.R.A.
in dialysis patients (pts), irrespective of mode of vascular access. F.
Locatelli et al. (SU-PO822. November 4: 10:00 a.m. - 12:00 p.m. PST.
Exhibit Hall, Moscone Center)
-- Once-monthly C.E.R.A. maintains stable hemoglobin (Hb) in patients
(pts) with chronic kidney disease (CKD), irrespective of baseline iron
levels. A. Nissenson et al. (SU-PO819. November 4: 10:00 a.m. - 12:00
p.m. PST. Exhibit Hall, Moscone Center)
-- C.E.R.A. maintains stable hemoglobin (Hb) in chronic kidney disease
(CKD), regardless of albumin or dialysis adequacy (Kt/V). W. Sulowicz
et al. (Publication Only)
-- Effect of baseline hemoglobin (Hb) on Hb stability in patients (pts)
with chronic kidney disease (CKD) receiving once-monthly C.E.R.A. N.W.
Levin et al. (SU-PO817. November 4: 10:00 a.m. - 12:00 p.m. PST.
Exhibit Hall, Moscone Center)
-- Anemia correction wi
'/>"/>
| SOURCE Roche Copyright©2007 PR Newswire. All rights reserved |